(HealthDay)—In infants with cystic fibrosis (CF), preventive inhalation with hypertonic saline (HS) during the first months of life is safe and well tolerated and results in clinical improvements, according to a study recently ...
Dec 14, 2018
0
0
Researchers at Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago, and colleagues, used a blood test and microarray technology to identify distinct molecular signatures in ...
Dec 13, 2018
0
1
Celiac disease is a severe autoimmune disorder of the intestine. It occurs when people develop sensitivity to gluten, a substance found in wheat, rye, and barley. An international research team from Italy and France has now ...
Nov 30, 2018
0
2
Antibiotics have emerged as potentially lifespan-enhancing drugs, according to the results of new research carried out in the UK.
Nov 28, 2018
2
3095
Children's Hospital Colorado (Children's Colorado) pediatric gastroenterologist, Michael Narkewicz, MD, recently shared results of the Prospective Study of Ultrasound to Predict Hepatic Cirrhosis in Cystic Fibrosis (PUSH), ...
Nov 12, 2018
0
0
For healthy people, mucus is our friend. It traps potential pathogens so our airways can dispatch nasty bugs before they cause harm to our lungs. But for people with conditions such as cystic fibrosis (CF) and chronic obstructive ...
Nov 12, 2018
1
103
Babies with cystic fibrosis may breathe better by inhaling hypertonic saline, according to a randomized controlled trial conducted in Germany and published in the American Thoracic Society's American Journal of Respiratory ...
Nov 9, 2018
0
0
The majority of patients with cystic fibrosis may not achieve blood concentrations of antibiotics sufficiently high enough to effectively fight bacteria responsible for pulmonary exacerbations, leading to worsening pulmonary ...
Nov 6, 2018
0
0
A new triple-combination drug treatment being trialled at the Mater Hospital in Brisbane could increase the life expectancy of patients with cystic fibrosis.
Oct 19, 2018
0
48
(HealthDay)—In what researchers are calling a "breakthrough," two preliminary trials have found that either of two triple-drug regimens could potentially benefit 90 percent of people with cystic fibrosis.
Oct 18, 2018
0
9
